Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2004, Vol. 2 ›› Issue (2): 103-105.doi: 10.3736/jcim20040208

• Original Clinical Research • Previous Articles     Next Articles

Treatment of non-small-cell lung cancer with chemotherapy and Sansheng Huatan Decoction

Wei-ming Fang1, Wei-ping Wang2, Bing-wei Yan1, Jian-yuan Zhou1   

  1. 1. Department of Internal Medicine, District Hospital of North Caoxi Road, Shanghai, 200030, China
    2. Department of Oncology, Shanghai Hospital of Traditional Chinese Medicine, Shanghai 200071, China
  • Online:2004-03-20 Published:2018-10-25

:Objective: To observe the clinical effect of Chinese medicine Sansheng Huatan Decoction combined with chemotherapy in treating advanced primary non-small-cell lung cancer and to evaluated the effect of Sansheng Huatan Decoction increasing clinical effect and decreasing toxicity in chemotherapy for non-small-cell lung cancer. Methods: One hundred and sixty patients of advanced primary non-small-cell lung cancer proved by pathological examination were randomized into two groups. The treatment group was treated with Sansheng Huatan Decoction and chemotherapy, and the control group was treated only with chemotherapy. The clinic effect, life quality, natural killer (NK) activities, liver and kidney functions, and blood routine test of the 2 groups were evaluated. Results: The clinical effective rates of the treatment and control groups were 56.7% and 48.2% respectively, and there was no statistic significance (P>0.10). The life quality, NK activities and blood routine test of the treatment group were better than those of the control group. Conclusion: Sansheng Huatan Decoction combined with chemotherapy is a better treatment for non small cell lung cancer as compared with chemotherapy.

Key words: Sansheng Huatan Decoction, non-small-cell lung cancer, integrated traditional Chinese with western medicine

CLC Number: 

  • R734.2

Tab 1

Therapeutic effects of 2 groupsCase(%)"

GroupClinical stagenComplete remissionPartial remissionStable diseaseProgressive disease
Treatment group
II33( 2.9)000
IIIa245( 4.8)16(15.4)2(1.9)1(0.9)
IIIb335( 4.8)19(18.2)6(5.8)3(2.9)
IV44011(10.6)28(26.9)5(4.8)
Total10413(12.5)46(44.2)36(34.6)9(8.7)
Control group
II11(1.8)000
IIIa143(5.3)7(12.5)3( 5.4)1(1.8)
IIIb202(3.5)9(16.2)7(12.5)2(3.5)
IV2105(8.9)13(23.2)3(5.3)
Total566(10.6)21(37.6)23(41.2)6(10.6)

Tab 2

Blood toxicity of 2 groups Case(%)"

GroupGradation of toxicityLeukocytePlateletHemoglobin
Treatment group(n=104)
016(15.3)20(19.2)42(40.4)
I39(37.5)32(30.8)37(35.6)
II26(25.0)48(46.2)22(21.1)
III15(14.5)2(1.9)2(1.9)
IV8(7.7)2(1.9)1(1.0)
Control group(n=56)
07(12.5)16(28.5)16(28.5)
I9(16.1)14(25.0)22(39.2)
II16(28.5)16(28.6)13(23.2)
III18(32.2)9(16.1)4(7.2)
IV6(10.7)1(1.8)1(1.8)

Tab 3

Changes of liver and kidney function in 2 groups (ヌ±S)"

GroupnTBIL(μmol/L)ALT(U/L)BUN(mmol/L)Cr(μmol/L)
Treatment group
Before treatment10416.9±8.952.6±6.75.2±1.995±28
After treatment10415.4±7.651.7±10.55.4±2.3104±34
Control group
Before treatment5615.9±6.951.9±23.35.3±1.789±36
After treatment5619.7±7.269.4±29.46.2±2.1114±32
[1] 上海市肿瘤研究所流行病学研究室.1999年上海市市区恶性肿瘤发病率[J].肿瘤,2002,5(3):259
doi: 10.3781/j.issn.1000-7431.2002.03.037
[2] 韩明权, 苏晋梅, 黄海茵, 等.序贯化放疗结合中药治疗54例晚期非小细胞肺癌患者的预后分析[J].中西医结合学报,2003,1(3):195-198
Han MQ, Su JM, Huang HY, et al.Prognostic analysis of advanced non small cell lung cancer treated by sequential chemo-radiation therapy cimbined with tradtional Chinese medicine: A report of 54 cases[J].Zhong Xi Yi Jie He Xue Bao,2003,1(3):195-198
[3] 秦笃祥, 李道堂.临床胸部肿瘤学(第1版)[M].济南: 山东科学技术出版社,1995,(第1版):257-258
[4] 中华人民共和国卫生部医政司编.中国常见恶性肿瘤诊疗规范(第9分册)(第1版)[M].北京: 北京医科大学、中国协和医科大学联合出版社,1991,(第1版):10-13
[1] Ming Zhang, Zhen-ye Xu, Bing Bai, Yun Dong. Feiyanning Decoction down-regulates the expressions of phosphorylated Akt and hypoxia inducible factor-1α proteins in transplanted lung adenocarcinoma in nude mice. Journal of Chinese Integrative Medicine, 2008, 6(6): 616-620.
[2] Yu Hao, Ping Wang, Jun Wu, Quan-ying Qiu. Effects of ginsenoside and berberine on secretion of immunosuppressive cytokines in lung carcinoma cell line PG. Journal of Chinese Integrative Medicine, 2008, 6(3): 278-282.
[3] Zhu-yi Zhang, Shi-qing Yu, Li-yun Miao, Xiao-ying Huang, Xiao-ping Zhang, Yu-ping Zhu, Xiao-hong Xia, Dan-qi Li. Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(2): 134-138.
[4] Mu-yun Zhu, Zheng-hua Jiang, Yuan-wen Lu, Yuan Guo, Jun-ji Gan. Matrine and anti-tumor drugs in inhibiting the growth of human lung cancer cell line. Journal of Chinese Integrative Medicine, 2008, 6(2): 163-165.
[5] Kai-wen Hu, Fen Wang, Yang Cao, Xiu-lan He, Ming-huan Zuo, Wen-qiang Chen. Risk factors of traditional Chinese medical syndromes in moderate and advanced lung cancer patients with concurrent fungal pneumonia. Journal of Chinese Integrative Medicine, 2004, 2(5): 337-339.
[6] Ming-quan Han, Jin-mei Su, Hai-yin Huang, Wei-hong Long, Li-ping Qin, Ping Qin, Wei Liu, Zhao-ying Sheng. Prognostic analysis of advanced non small cell lung cancer treated by sequential chemo-radiation therapy combined with traditional Chinese medicine: A report of 54 cases. Journal of Chinese Integrative Medicine, 2003, 1(3): 195-198.
[7] Ming-quan Han, Jia-xiang Liu, Hong Gao, Shan-xiang Chen, Yan-wei Zhu, Ling Xu. Effects of Yifei Kangliu Oral Liquid on cell cycle and protein-nucleic acid synthesis of experimental lung cancer. Journal of Chinese Integrative Medicine, 2003, 1(3): 205-208.
[8] Zhen-ye Xu. Evidence-based medicine and treatment of lung cancer. Journal of Chinese Integrative Medicine, 2003, 1(2): 151-154.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Hao Li, Ming-jiang Yao, Wen-ming Zhao, Jie Guan, Lin-lin Cai, Ling Cui. A randomized, controlled, double-blind trial of Huannao Yicong capsule in senile patients with mild cognitive impairment. Journal of Chinese Integrative Medicine, 2008, 6(1): 25-31
[2] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[3] SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[4] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[5] Ya-bing Zhou, Jian-er Yu, Jie Wu, Li Bai, Li-li Huo, Xin-guang Zhang, Li-qing Li . Effects of Chinese herbal medicine Bushen Gubiao Recipe on toll-like receptor 4 and CD4 +CD25 +foxp3 +regulatory T cells in mice with recurrent respiratory tract infections. Journal of Chinese Integrative Medicine, 2010, 8(11): 1053-1059
[6] Nian-hong Wang , Jun-tao Yan , Wu-quan Sun , Yong-shan Hu , Jun Xia , Li-cheng Wei , Jie Jia , Gui-lin Ouyang , Yong He , Yan-ming Guo , Jie Xu . Effects of early application of Tuina treatment on quadriceps surface myoelectricity in patients after total knee arthroplasty: a randomized controlled trial. Journal of Chinese Integrative Medicine, 2012, 10(11): 1247-1253
[7] Kishan Lal Tiwari, Shailesh Kumar Jadhav, Veenu Joshi. An updated review on medicinal herb genus Spilanthes. Journal of Chinese Integrative Medicine, 2011, 9(11): 1170-1178
[8] Lei Chen, Xiao-ying Bi, Li-xun Zhu, Yi-qing Qiu, Su-ju Ding, Ben-qiang Deng. Flavonoids of puerarin versus tanshinone ⅡA for ischemic stroke: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2011, 9(11): 1215-1220
[9] Mei-jun Lü, Hui-yong Zhang, Zhe Zhang, Guan-lin Yang. Measurement of health-related quality of life in coronary heart disease: A review. Journal of Chinese Integrative Medicine, 2011, 9(12): 1277-1285
[10] Chang-quan Ling. Cancerous toxin is the key pathogenic factor of malignant tumor. Journal of Chinese Integrative Medicine, 2008, 6(2): 111-114